WO2024100446 - DIAGNOSTIC ALGORITHMS FOR DETERMINING AND TREATING CLINICALLY SIGNIFICANT PROSTATE CANCER BASED ON SIALYLATED AND FUCOSYLATED PROSTATE SPECIFIC ANTIGEN
National phase entry is expected:
Publication Number
WO/2024/100446
Publication Date
16.05.2024
International Application No.
PCT/IB2022/062894
International Filing Date
29.12.2022
Title **
[English]
DIAGNOSTIC ALGORITHMS FOR DETERMINING AND TREATING CLINICALLY SIGNIFICANT PROSTATE CANCER BASED ON SIALYLATED AND FUCOSYLATED PROSTATE SPECIFIC ANTIGEN
[French]
ALGORITHMES DE DIAGNOSTIC POUR DÉTERMINER ET TRAITER UN CANCER DE LA PROSTATE CLINIQUEMENT SIGNIFICATIF SUR LA BASE D'UN ANTIGÈNE SPÉCIFIQUE DE LA PROSTATE SIALYLÉ ET FUCOSYLÉ
Applicants **
GLYCA INC.
Inventors
KLASSEN, John
LI, Zhixiong
Priority Data
63/423,766
08.11.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2831 | |
| EPO | Filing, Examination, Granting | 16869 | |
| Japan | Filing, Examination, Granting | 2605 | |
| South Korea | Filing, Examination, Granting | 2931 | |
| USA | Filing, Examination, Granting | 12540 |
Total:
37,776
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein are an α2-3 disialylated PSA protein standard and an α2-6 disialylated PSA protein standard, as well as various methods for measuring the relative (fractional) amount of the total N-acetylneuraminic acid (Neu5Ac) that is α2-3-linked N-acetylneuraminic acid (α2-3-linked Neu5Ac) and is α2-6-linked N-acetylneuraminic acid (α2-6-linked Neu5Ac) on PSA present in a blood serum or plasma sample, which is useful for determining whether a subject has a low risk (GG1), intermediate risk (GG2) or a high risk (GG3, 4 or 5) prostate cancer and/or determining and/or treating whether a human subject suspected of having prostate cancer should receive a needle biopsy. Also included are methods of monitoring and treating a prostate cancer patient post prostate cancer removal surgery for need of additional cancer treatment.[French]
L'invention concerne un étalon protéique PSA α2-3 disialylé et un étalon protéique PSA α2-6 disialylé, ainsi que diverses méthodes de mesure de la quantité (fractionnelle) relative de l'acide N-acétylneuraminique total (Neu5Ac) qui est l'acide N-acétylneuraminique lié à α2-3 (Neu5Ac lié à α2-3) et qui est l'acide N-acétylneuraminique lié à α2-6 (Neu5Ac lié à α2-6) sur le PSA présent dans un échantillon de sérum ou de plasma sanguin, ce qui est utile pour déterminer si un sujet présente un cancer de la prostate à faible risque (GG1), à risque intermédiaire (GG2) ou à risque élevé (GG3, 4 ou 5) et/ou déterminer et/ou traiter si un sujet humain susceptible d'avoir un cancer de la prostate doit subir une biopsie par aspiration. L'invention concerne également des méthodes de surveillance et de traitement d'un patient atteint d'un cancer de la prostate après une chirurgie d'élimination du cancer de la prostate nécessitant un traitement anticancéreux supplémentaire.